Effective combinatorial immunotherapy for castration-resistant prostate cancer
X Lu, JW Horner, E Paul, X Shang, P Troncoso, P Deng… - Nature, 2017 - nature.com
A significant fraction of patients with advanced prostate cancer treated with androgen
deprivation therapy experience relapse with relentless progression to lethal metastatic …
deprivation therapy experience relapse with relentless progression to lethal metastatic …
Novel dual Src/Abl inhibitors for hematologic and solid malignancies
S Schenone, C Brullo, F Musumeci… - Expert opinion on …, 2010 - Taylor & Francis
Importance of the field: c-Src and Bcr-Abl are two non-receptor or cytoplasmic tyrosine
kinases (TKs) that play important roles in the development of solid and hematological …
kinases (TKs) that play important roles in the development of solid and hematological …
[HTML][HTML] Molecular profiling of childhood cancer: Biomarkers and novel therapies
Background Technological advances including high-throughput sequencing have identified
numerous tumor-specific genetic changes in pediatric and adolescent cancers that can be …
numerous tumor-specific genetic changes in pediatric and adolescent cancers that can be …
Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes
Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers,
which hinders the development of targeted therapies and novel risk stratification strategies …
which hinders the development of targeted therapies and novel risk stratification strategies …
Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against …
c-Src is a tyrosine kinase belonging to the Src-family kinases. It is overexpressed and/or
hyperactivated in a variety of cancer cells, thus its inhibition has been predicted to have …
hyperactivated in a variety of cancer cells, thus its inhibition has been predicted to have …
Oncogenic Ras/Src cooperativity in pancreatic neoplasia
DJ Shields, EA Murphy, JS Desgrosellier, A Mielgo… - Oncogene, 2011 - nature.com
Pancreas cancer is one of the most lethal malignancies and is characterized by activating
mutations of Kras, present in 95% of patients. More than 60% of pancreatic cancers also …
mutations of Kras, present in 95% of patients. More than 60% of pancreatic cancers also …
Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery
DM Patterson, JM Shohet… - Current protocols in …, 2011 - Wiley Online Library
Neuroblastoma is the most common pediatric abdominal solid tumor. This aggressive
embryonal malignancy of neural crest origin has a peak age of onset of 22 months, and …
embryonal malignancy of neural crest origin has a peak age of onset of 22 months, and …
Cell proliferation in neuroblastoma
LL Stafman, EA Beierle - Cancers, 2016 - mdpi.com
Neuroblastoma, the most common extracranial solid tumor of childhood, continues to carry a
dismal prognosis for children diagnosed with advanced stage or relapsed disease. This …
dismal prognosis for children diagnosed with advanced stage or relapsed disease. This …
Subtype of neuroblastoma cells with high KIT expression are dependent on KIT and its knockdown induces compensatory activation of pro-survival signaling
Neuroblastoma (NB) is a pediatric cancer with high clinical and molecular heterogeneity,
and patients with high-risk tumors have limited treatment options. Receptor tyrosine kinase …
and patients with high-risk tumors have limited treatment options. Receptor tyrosine kinase …
PPP2CA is a novel therapeutic target in neuroblastoma cells that can be activated by the SET inhibitor OP449
C Galiger, M Dahlhaus, MP Vitek, KM Debatin… - Frontiers in …, 2022 - frontiersin.org
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and has a
poor prognosis in high-risk cases, requiring novel therapies. Pathways that depend on …
poor prognosis in high-risk cases, requiring novel therapies. Pathways that depend on …